Stablepharma, the Fridge-free Vaccine Company, is delighted to announce another new member to the Team. Richard Amaee joins as Programme Manager and will be responsible for the development of Stablepharma’s reformulated, fridge-free SPVX02 vaccine for Tetanus diphtheria, working closely with our Chief Scientific Officer (CSO), Dr Arcadio Garcia de Castro.
“This is great news for Stablepharma, as we broaden our team and inhouse expertise in both Madrid R&D centre, and our UK Headquarters in London,’ said Özgür Tuncer, CEO & Executive Director. ‘Richard will initially focus on the development of our Tetanus diphtheria vaccine (SPVX02), which is planned to enter clinical trials in 2023’. ‘Our StablevaX™-Td vaccine (SPVX02) has been shown to be thermostable up to 12 months at +45°C without any impact on potency’, added Özgür.
With a Biochemistry PhD (Cambridge) Richard has extensive knowledge and experience working with novel and generic pharmaceutical products, including injectable vaccines and is well versed in CMC, Regulatory and Quality processes.
“We are delighted to welcome Richard on board, as we progress towards the development, manufacture and commercialisation of our portfolio of fridge-free vaccines”, added Nick Child, VP & Co-Founder of Stablepharma. ‘We have identified over 60 existing approved vaccines suitable for our StablevaX™ technology’.